^
CANCER:

Endometrial Adenocarcinoma

Related cancers:
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 overexpression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
MSI-H/dMMR
Endometrial Adenocarcinoma
AZD1775
Sensitive: C3 – Early Trials
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C3 – Early Trials
ER positive
Endometrial Adenocarcinoma
letrozole + zoledronic acid
Sensitive: C4 – Case Studies
MSH6 F1088fs
Endometrial Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
HER-2 amplification
Endometrial Adenocarcinoma
lapatinib
Sensitive: D – Preclinical
HER-2 amplification
Endometrial Adenocarcinoma
trastuzumab + lapatinib
Sensitive: D – Preclinical
HER-2 amplification
Endometrial Adenocarcinoma
afatinib
Sensitive: D – Preclinical